Rep. C. Scott Franklin Purchases Shares of Novo Nordisk A/S (NYSE:NVO)

Key Points

• Representative C. Scott Franklin purchased shares of Novo Nordisk A/S (NYSE:NVO) between $15,001 and $50,000 on August 4th, according to a filing disclosed on August 14th.
• Despite a 2.9% increase in stock price, Novo Nordisk A/S reported earnings of $0.97 per share, surpassing analyst expectations of $0.93.
• The company's recent dividend payout was announced at $0.4119, representing a significant dividend yield of 240.0%.

Representative C. Scott Franklin (R-Florida) recently bought shares of Novo Nordisk A/S NYSE: NVO. In a filing disclosed on August 14th, the Representative disclosed that they had bought between $15,001 and $50,000 in Novo Nordisk A/S stock on August 4th. The trade occurred in the Representative's "FIDELITY TRADITIONAL IRA" account.

Representative C. Scott Franklin also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Purchased $1,001 - $15,000 in shares of Novo Nordisk A/S NYSE: NVO on 8/4/2025.
• Sold $15,001 - $50,000 in shares of Comcast NASDAQ: CMCSA on 8/4/2025.
• Sold $1,001 - $15,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $50,001 - $100,000 in shares of United Parcel Service NYSE: UPS on 7/22/2025.
• Sold $15,001 - $50,000 in shares of Visa NYSE: V on 6/16/2025.
• Sold $15,001 - $50,000 in shares of Apple NASDAQ: AAPL on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Alphabet NASDAQ: GOOG on 6/16/2025.
• Sold $1,001 - $15,000 in shares of Merck & Co., Inc. NYSE: MRK on 6/16/2025.
• Sold $15,001 - $50,000 in shares of McDonald's NYSE: MCD on 6/16/2025.

Novo Nordisk A/S Stock Down 0.9%

NYSE NVO traded down $0.4820 on Wednesday, reaching $54.2980. The stock had a trading volume of 14,039,234 shares, compared to its average volume of 28,881,536. The business has a 50 day moving average price of $63.54 and a 200 day moving average price of $69.81. The company has a current ratio of 0.78, a quick ratio of 0.56 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a market capitalization of $242.44 billion, a price-to-earnings ratio of 14.92, a P/E/G ratio of 1.88 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, beating analysts' consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th will be paid a $0.4119 dividend. The ex-dividend date is Monday, August 18th. This represents a yield of 240.0%. Novo Nordisk A/S's payout ratio is 22.53%.

Hedge Funds Weigh In On Novo Nordisk A/S

Large investors have recently made changes to their positions in the business. Strategic Investment Solutions Inc. IL lifted its position in shares of Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Park Square Financial Group LLC acquired a new position in Novo Nordisk A/S in the 4th quarter valued at approximately $29,000. Transce3nd LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $33,000. North Capital Inc. bought a new stake in shares of Novo Nordisk A/S in the 1st quarter worth approximately $27,000. Finally, Copeland Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock worth $27,000 after acquiring an additional 255 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the company. BNP Paribas Exane upgraded Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research note on Wednesday, August 13th. Wall Street Zen cut Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Dbs Bank cut Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. HSBC cut Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 price target for the company. in a research report on Thursday, July 31st. Finally, TD Cowen reduced their price target on Novo Nordisk A/S from $105.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday. Three analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $81.00.

About Representative Franklin

Scott Franklin (Republican Party) is a member of the U.S. House, representing Florida's 18th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Franklin (Republican Party) is running for re-election to the U.S. House to represent Florida's 18th Congressional District. He declared candidacy for the 2026 election. Scott Franklin was born in Thomaston, Georgia. Franklin graduated from Lakeland High School. He served in the U.S. Navy from 1986 to 2000 and the U.S. Navy Reserve from 2000 to 2012. Franklin earned a B.S. from the United States Naval Academy in 1986 and an M.B.A. from Embry-Riddle Aeronautical University in 1994. Franklin's career experience includes owning an insurance agency and working as a naval aviator with the U.S. Navy.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.